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ABSTRACT 
Allergic rhinitis (AR) is a global health problem that causes major disability 
worldwide. Nasal obstruction, secretion and itching are characterizing features of 
the disease. The development and severity of AR are determined by a complex 
interaction between environmental and genetic factors and the heritability for AR 
has been estimated to be high. Genetic association studies are commonly used to 
investigate complex disease. Most association studies have focused on common 
variation in the form of single nucleotide polymorphisms (SNPs), where allele 
and genotype frequencies are compared between cases and controls. More than 
100 SNPs have previously been associated with AR. In the first study of this 
thesis, the general reproducibility of previous AR associations were evaluated. 
The overall result showed that very few of the investigated SNPs were associated 
with AR in the study populations. The study also indicated that odds ratios were 
inflated in most of the original studies, and concordance of risk alleles between 
the studies was low. Since the genetic background of asthma has been far more 
investigated compared to the genetics of AR and since asthma is closely related 
to AR, the second study investigated genetic variation in 21 highly replicated 
asthma-associated genes for associations also in AR. Only two genes were 
identified as potential links between AR and asthma, indicating the different 
genetic make-up of these diseases. Three meta studies of genome-wide 
association studies (mGWAS) recently identified a total of 47 index SNPs 
associated with different AR phenotypes. In the third study, these SNPs were 
investigated in a replication study using the same SNPs and the same phenotype 
definitions as in the mGWAS. Two out of four loci (TLR1-TLR6 and HLA-
DQA1-HLA-DQB1) identified by all three original studies were also detected in 
the replication study. This suggests a central role of these loci in the 
epidemiology of allergic disease. In addition, associations between genetic 
variation in the SSTR1-MIPOL1 and TSLP-SLC25A46 loci and age at which the 
allergic symptoms started was also identified. This was the first report of age at 
onset effects in AR. The Toll-like receptors (TLRs) have earlier been 
investigated for their involvement in different allergic diseases. In the fourth 
study, common genetic variation in the TLR genes was investigated for 
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association with AR in two ethnically different populations. The TLR7-TLR8 
locus was identified as associated with AR in both populations in a sex-specific 
manner. In addition, weak associations were also observed for TLR1 and TLR6. 
In the fifth study of this thesis, rare variation in both the coding sequences and 
the putative promoter regions of the TLR genes were investigated using 
sequence data from 288 AR patients and a European subset (EUR) of the 1000 
Genomes project. The promotor region of TLR10 showed a significant 
accumulation of SNPs with minor allele frequency ≤ 1% in the AR population 
compared to the EUR population. Another potential accumulation was a 
nonsense mutation, S324* in TLR1, estimated to 5 copies in the AR population 
but none in the EUR populations. This indicates that both common and rare 
SNPs in the TLR genes contribute to AR. In summary, this thesis demonstrates 
that both rare and common variation are associated with AR and highlights the 
importance of the TLR10-TLR1-TLR6 locus in the development of the disease. It 
also emphazises the need for large and well-characterized populations in 
association and replication studies.  
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LIST OF ABBREVIATIONS 
AFR African 
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tSNP Tag singel nucleotide polymorphism 
  
 8 
  
  9 
1 INTRODUCTION 
1.1 THE HUMAN GENOME 
The human genome is composed of 22 pairs of autosomal chromosomes and two 
sex chromosomes (X and Y chromosomes). Somatic cells are diploid, meaning 
that they contain two copies of each chromosome, one copy inherited from the 
father and one from the mother resulting in a total of 46 chromosomes in each 
cell. The Human Genome Project (HGP), initiated in 1990, aimed to produce a 
draft sequence of the human genome. This was by far the largest genome to be 
sequenced at that time. In 2001 the first draft sequence covering approximately 
94% of the human genome was released [1]. The same year Celera genomics, 
which was a private initiative led by J. Craig Venter, released a 2.98 billion base-
pair assembly of the human genome. Celera used a different strategy than HGP 
and also used the information released by HGP to assemble their sequence data 
into an almost complete genome sequence [2]. The latest assembly of the human 
genome consists of 3.4 billion base pairs (bp) and encodes approximately 20 500 
genes according to the Genome Reference Consortium Human Build 38 
(GRCh38) Assembly.  
1.2 GENETIC VARIATION 
Most sequence variants of an organism are neutral or nearly neutral. A mutation 
can modify a gene or its expression or even delete an entire gene. Here the term 
mutation is used when sequence variants are harmful for the organism, otherwise 
the term variant or polymorphism is more appropriate to use. Such detrimental 
mutations are normally rare in the population and often affects the function or 
expression level of the protein. There are a number of different types of genetic 
variants like single nucleotide polymorphisms (SNPs), insertions or deletions of 
single nucleotides or nucleotide-stretches of various length, length variations of 
tandem repeated sequences (micro and mini satellites) and copy number variants 
(CNVs). Mutation of DNA is a random event and different types of mutations 
have different mutation rates, i.e. the frequencies are type-dependent. SNPs are 
the most abundant form of genetic variation and are also the most common form 
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of variation analyzed in genetic association studies. A SNP is a variant position 
in the DNA sequence. It typically has two alleles, with the least abundant allele 
present at a frequency ≥ 1% in the population. It has been estimated that there is 
on average one SNP every 300 bp in the human genome when the total human 
population is investigated. If instead a single individual is compared with the 
reference sequence, a total of ca. 3x106 SNPs are present equivalent to one SNP 
every 1000 bp in the genome. With the exception of sex chromosomes in males, 
humans have two copies of each chromosome and both alleles can therefore be 
present in the same individual when looking at a specific SNP. An individual has 
one allele on one chromosome and one allele on the other, which is referred to as 
a genotype. Consequently, there are three different states for a genotype: 
homozygous for the common allele (e.g. AA), heterozygote (AG) and 
homozygous for the rare allele (GG).  
1.2.1 Haplotypes 
The set of alleles residing on a specific chromosome or a specific part of a 
chromosome is called a haplotype. For a sub-region of a chromosome with SNP 
alleles at a number of different loci, the alleles define the possible haplotypes for 
that region. For example, for two SNPs with the alleles A/G and C/T there are 
four different possible haplotypes for that region: A-C, A-T, G-C and G-T. The 
original haplotype is changed first at one of the positions and then at the other 
position resulting in three different haplotypes. The fourth haplotype is in most 
cases created through recombination between the two positions. The frequencies 
of the haplotypes depend on the frequencies of each allele in the population. 
New haplotypes for a chromosome region arise by the accumulation of 
additional mutations and recombination events.  
1.2.2 Linkage disequilibrium 
Alleles located close to each other are more likely to be co-inherited than alleles 
that are located farther apart. Such non-random association of alleles is known as 
linkage disequilibrium (LD). Each time recombination occurs between two loci, 
LD is also weakened between them. LD is calculated as the difference between 
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the frequency of haplotypes carrying the alleles A and B at two different loci and 
the product of the frequencies of those alleles, i.e. DAB = pAB - pApB. However, D 
is often not the most convenient statistic to use for describing LD since the range 
of values for D depends on the allele frequencies and is therefore not optimal 
when comparing LD at different pairs of loci. A number of additional statistics to 
describe LD has been proposed, among them D´ and r2 which are both 
commonly used. D´ is the ratio of D to the largest possible value of D given the 
allele frequencies (the smaller of pA(1-pB) and pB(1-pA)). The other commonly 
used statistic, r2, represents the correlation coefficient between two loci and is 
calculated as: r2 = D2/ pA(1-pA)pB(1-pB). D´ is a convenient measure since D´=1 
indicates that no historical recombination has occurred between the loci in the 
ancestors of the sample, which is often referred to as perfect LD. However, D´ is 
defined in such a way that D´ = 1 if two or three of the possible haplotypes are 
observed and it is < 1 if all four haplotypes are present. The r2 statistic on the 
other hand takes the value of 1 only when two of the possible haplotypes are 
present [3,4]. 
1.2.3 The HapMap project 
In 2005 the International HapMap Consortium released the first haplotype map 
of the human genome. Phase I of HapMap describes the common patterns of 
genetic variation and LD patterns in 269 individuals from four different 
populations: 90 individuals from Utah with Northern and Western European 
ancestry, 90 Yoruban individuals from Ibadan, 44 Japanese individuals from 
Tokyo and 45 Han Chinese individuals from Beijing. The project genotyped 
more than 1 million SNPs with minor allele frequencies (MAFs) ≥ 5%. The 
release of HapMap data was a great resource for designing genotyping efforts in 
genetic association studies. Since different SNPs are associated through LD, tag-
SNPs (tSNPs) can be used to capture a large fraction of the variation in any 
given region. Thus, tSNPs can serve as proxies for SNPs not selected for 
genotyping. There are a number of different algorithms for the selection of 
tSNPs. Pairwise-tagging is a commonly used method, where tSNPs are selected 
until all common SNPs are highly correlated (ex. r2 > 0.8) with the selected 
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tSNPs. For example, to capture all common SNPs in the Chinese and Japanese 
samples of the HapMap Phase I data would require 260 000 tSNPs by using a r2-
value of 0.8. By using a lower r2-value of 0.5 the number of tSNPs decreases to 
159 000 for the same populations [5]. In Phase II of HapMap an additional 2.1 
million SNPs were genotyped in the same populations. The resulting SNP 
density of Phase II was approximately one SNP per kilobase-pair and provides a 
better representation of rare variants compared to Phase I [6]. The knowledge of 
human genetic variation was still limited with respect to variant type, frequency 
and population diversity. Even though rare variants are considered as major 
contributors for common diseases, focus has been on common variation. In 
Phase III of the HapMap project, 1.6 million SNPs were genotyped in 1184 
individuals from 11 different populations and also ten 100 kbp regions were 
sequenced in 692 individuals in order to create a high-resolution map of genetic 
variation including rare variants [7].  
1.2.4 Sequencing projects 
Ten years after the first draft human genome sequence was published, the 1000 
Genomes Project Consortium published the results from the pilot phase of an 
extensive sequencing project [8]. Following the introduction of next-generation 
sequencing technology, the cost of sequencing decreased dramatically. The 1000 
Genomes Project was the first project to provide a comprehensive resource on 
human genetic variation determined by whole-genome sequencing in a large 
number of individuals. The aim of the project was to characterize over 95% of 
sequence variation with an allele frequency of ≥1% in five different populations: 
European, East Asian, South Asian, West Africans and Americans. The pilot 
phase of the project was divided in three different projects. In the first project 
low-coverage whole-genome sequencing (2-4X) was performed in 179 
individuals. The second and third project included deep sequencing of six 
individuals in two families and exon sequencing of 8140 exons in 697 
individuals [8]. In 2012, the 1000 Genomes Project Consortium released the 
complete genomes of 1092 individuals from 14 different populations capturing 
up to 98% of accessible SNPs at a frequency of ≥1%. The data was generated 
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using a combination of low-coverage (2-6X) whole-genome sequence data and 
high coverage (50-100X) exome sequence data and SNP genotyping for 
validation. The sequencing detected 38 million SNPs, 1.4 million short insertions 
and deletions and more than 14 000 large deletions [9]. In 2014 the full project 
was released containing sequence data from 2535 individuals from 26 different 
populations (http://www.1000genomes.org). UK10K is another large sequencing 
project that was initiated in 2010. The primary goal of the project was to 
sequence the whole genome of 4000 samples from the TwinsUK and ALSPAC 
cohorts to 6X sequencing depth and 6000 exomes of extreme phenotypes for a 
number of specific conditions (http://www.uk10k.org/). At the American Society 
of Human Genetics conference in October 2014, the Haplotype Reference 
Consortium presented a database containing about 50 million genetic variants 
collected from whole-genome sequence data generated by 23 research 
collaborations. At the same time, the Exome Aggregation Consortium released a 
public database containing the exome sequences of approximately 63 000 
samples [10].    
1.3 DISEASE INHERITANCE 
Genetic diseases can be inherited in a number of different ways. When a disease 
is due to a single mutation in a gene, the disease is referred to as monogenic or 
Mendelian. The inheritance pattern of monogenic diseases follows Mendel’s 
laws and can be traced in familial pedigrees. Polygenic diseases have a 
complicated pattern of inheritance since disease is due to mutations in multiple 
genes, and in complex diseases different environmental factors also acts on 
disease status. 
1.3.1 Monogenic diseases 
Monogenic diseases are classified according to their inheritance patterns. In 
dominant inherited diseases, one copy of the defective gene is enough to cause 
disease. Even if an individual has one healthy copy of the gene and one defective 
copy, the individual will suffer from disease. A disease inherited in an autosomal 
recessive manner requires that both copies of the gene are defective. Autosomal 
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recessive diseases are generally rare in the population and the defective genes 
can hide in carriers harboring only one copy of the defective gene. In recessive 
X-linked diseases males are more frequently affected than females, since males 
only have one copy of the X-chromosome. Dominant X-linked diseases requires 
only one defective copy just as in the case of autosomal dominant diseases, but 
the inheritance pattern differ since males only have one copy of the X-
chromosome whereas females have two.  
1.3.2 Complex diseases 
In complex disease like diabetes, asthma and allergic rhinitis, the inheritance 
pattern is not as straight forward as in monogenic disease even though the 
disease tends to accumulate in families. Contrary to in the case of monogenic 
disease where the effect of one mutation is enough to cause the disease, the 
combined effect of mutations in multiple genes in combination with different 
environmental factors causes disease in the case of complex disease. This 
implies that the effect of a single mutation is small and therefore difficult to 
detect in genetic studies. The primary focus for the investigation of complex 
disease has for long been on investigating common variation according to the 
Common Disease, Common Variant (CDCV) hypothesis, which states that 
common complex diseases are due to common variants each with small to 
modest effects. The information gathered within the HapMap project in concert 
with technical advances made it possible to conduct genome-wide association 
studies (GWAS), which investigates common variation [11]. According to the 
Catalog of Published Genome-Wide Association Studies 
(http://www.genome.gov/gwastudies/) more than 2000 GWAS studies have been 
reported in the literature. Even though GWAS have been a successful strategy in 
identifying associations with various diseases, the collective associations only 
explain a minor fraction of the phenotypic variation in the population [11]. This 
lack of explanation for a large proportion of the phenotypic variation in complex 
diseases is referred to as the missing heritability and has been widely debated 
over the years. Epigenetic effects, rare variations and also entirely unforeseen 
sources have been suggested to account for this missing heritability [12]. In 
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contrast to the CDCV hypothesis, the Common Disease, Rare Variant (CDRV) 
hypothesis argues that multiple rare variants with relatively strong individual 
effects are the major contributors to common disease. Rare genetic variants in 
the form of CNVs have been associated with a number of diseases, especially 
neuropsychiatric diseases [11]. In the case of autism spectrum disorders a large 
number of rare CNVs have been identified. In contrast to SNPs identified 
through GWAS, the effect sizes have been reported to be 3 times higher for 
CNVs [13]. Multiple rare SNPs have also been linked to a number of different 
diseases including type 1 diabetes, colorectal cancer and tuberculosis [14-16].     
1.4 MOLECULAR GENETICS 
The polymerase chain reaction (PCR) invented by Kary Mullis in the mid 80’s is 
the basis for many of the techniques used in molecular biology today. PCR uses 
a heat-stable polymerase to synthesize copies of the target sequence in a cyclic 
three-step process involving a denaturation step where all DNA molecules are 
made single-stranded, an annealing step where the primers that specifies the 
target sequence is binding to template DNA and finally a synthesis step where a 
copy is made of each template strand. Since copies are made of both strands 
simultaneously the target sequence is amplified exponentially. The specificity of 
this process is determined by the single stranded primers that is designed to bind 
to a specific complementary sequence in the template DNA. The end result after 
25-35 cycles of the three-step process is an amplification of a specific DNA-
region to many millions of copies. This amplification is a prerequisite for many 
of the analysis techniques used within molecular genetics today [17]. 
Genotyping can be made using a great variety of different techniques. When a 
few SNPs are analyzed in many individuals a commonly used system is the 
TaqMan system. This system relies on two dual-labelled probes, one for each 
allele of a specific SNP. During PCR amplification of a DNA sequence that 
contains the SNP in question the two probes can bind to their respective 
complementary sequences and upon binding the probes are digested by the 
polymerase releasing a fluorophore. This fluorophore is quenched as long as it is 
bound to the probe, but after release and exposure to light of a suitable 
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wavelength it fluoresces. The fluorescence of the allele-specific fluorophores is 
registered and the genotypes of the samples determined. This system is highly 
precise and is often used to confirm genotype data generated by other techniques 
[17]. 
Another common genotyping system is the Sequenom multiplex primer-
extension method. Also this system relies on PCR amplification of target 
sequences containing the interrogated SNPs. After purification of the primary 
PCR products thereby eliminating the primers and dNTPs of the first reaction, an 
extension primer is elongated into the polymorphic site. This extension is made 
in the presence of a mixture of nucleotides where some of the nucleotides are 
elongating and some are terminating the growing chain of nucleotides. This 
creates allele-specific extensions of the primer and these differently sized 
molecules can then be detected by MALDI-TOF mass spectrometry. This whole 
process can be made in a multiplex fashion simultaneously recording the 
genotypes of up to 36 different SNPs. This genotyping system is much used in 
candidate gene studies and in replication studies where a couple of hundred 
SNPs are analyzed [18,19]. 
Microarray hybridization is used to interrogate many SNPs in parallel in a given 
sample. This is the technique typically chosen for GWAS since it can reach the 
very high numbers of SNPs (0.5-5 million) that are necessary to cover the human 
genome at a SNP density that is sufficient for this type of analysis. A microarray 
consists of millions of different unlabelled oligonucleotide probe populations 
that have been fixed to a surface within a high density grid format. Each square 
in this grid is covered with millions of identical copies of just one probe 
sequence. A test sample is genotyped on this array by first labelling the DNA 
fragments of the sample and then hybridizing denatured fragments onto the 
array. After a washing step that decreases non-specific binding of the labelled 
fragments, the remaining sample molecules are detected using a laser scanner. 
The emitted signals are then analyzed using digital image software to distinguish 
the binding of DNA fragments that differs in only one position, i.e. the different 
alleles of the interrogated SNP. There are a number of strategies to achieve the 
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high sequence specificity that is necessary to discriminate DNA sequences that 
are almost identical [20]. 
The ultimate test for polymorphisms is DNA sequencing [17]. For many years 
different variants of the dideoxy DNA sequencing strategy originally described 
by Fredric Sanger has been the primary sequencing technique. Also this 
technique relies on the initial PCR amplification of the studied DNA sequence. 
After purification of the PCR products with regard to primers and deoxy-
nucleotides, the actual sequencing reaction takes place. This reaction contains 
one sequencing primer that defines where DNA sequencing will take place and a 
mixture of deoxy- and dideoxy-nucleotides (elongators and terminators) that will 
be incorporated into the growing chains. All of the four bases are present both as 
elongators and terminators with the elongators present at a 100-fold surplus 
compared to the terminators. The four different terminator-bases are also labelled 
with four different base-specific fluorophores. Since termination is a random 
process, a set of DNA fragments will be created that are terminated at each 
position of the sequence under analysis. All of the fragment copies of a given 
length will be terminated in the same base and carry the same fluorophore. The 
fragment population will then be separated according to size using capillary 
electrophoresis and the fluorescent signals of the fluorophores detected as they 
pass in front of a detector after being separated on the capillary. After base-
calling the resulting DNA sequence is aligned to a reference sequence and 
interpreted for differences compared to the reference sequence. The analysis of 
both strands of a given DNA molecule results in high quality of the resulting 
sequence. This type of DNA sequencing, often called Sanger sequencing, is now 
mostly used to analyze the promoter and the exons of one or a few genes since 
the method is time-consuming and costly [17] . 
In the years 2005-2008 a number of new sequencing methods were developed. 
They are termed next-generation sequencing methods to acknowledge the fact 
that they are all massively-parallel and quite different from the Sanger method. 
The Ion Torrent sequencing technique, for example, is based on a complex 
mixture of DNA fragments where the individual fragments are amplified by 
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emulsion PCR producing millions of copies of individual DNA sequences each 
bound to single spheres. The DNA sequences of the spheres are then sequenced 
in parallel using flows of each base over vast collections of spheres. Since a 
hydrogen ion is released for each base that is incorporated into a growing chain 
the incorporation of bases can be determined by measuring the pH of the 
solution surrounding the sphere. This is made by a semiconductor pH sensor 
device located in close proximity to each sphere. This method allow very large 
numbers of sequences to be determined in parallel and lowers the costs for 
sequencing substantially [21,22]. 
1.5 GENETIC ANALYSIS 
Different types of study design and statistical methods have been developed and 
adopted for the identification of disease-causing genes or chromosomal regions 
harboring genetic variation influencing disease.  
1.5.1 Linkage studies 
Linkage studies uses related individuals to map genetic loci that predispose to 
disease. Two loci are linked if they are co-transmitted from parent to offspring 
more often than expected under independent inheritance. Another common way 
of expressing this is that, for two linked loci the recombination frequency 
between them is less than 0.5. In brief, by studying the segregation of genotyped 
markers through pedigrees and calculating recombination frequencies the 
relative positions of those markers can be inferred. Using this strategy, disease 
loci can be mapped relative to the genotyped markers. Linkage analysis is useful 
for the identification of wide regions harboring disease-causing genes that can be 
further investigated using other methods [23].  
1.5.2 Population association studies 
Population association studies use, in contrast to linkage studies, unrelated 
individuals for the identification of genetic variation that vary systematically 
between diseased individuals and control individuals. An observed association is 
either direct, i.e. the SNP itself influences the trait in question, or indirect, i.e. the 
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SNP is in LD with a genetic variant that influences the trait. Association studies 
are a major tool in identifying risk loci in complex diseases. Most association 
studies have focused on common variation in the form of SNPs, where allele and 
genotype frequencies are compared between cases and controls. A significantly 
higher frequency of one or the other allele in cases relative to in controls 
indicates an increased risk for disease in the presence of the specific allele [24]. 
Since association studies compare allele and genotype frequencies, it is 
important to ensure a common genetic background for cases and controls so that 
any observed differences are due to presence or absence of disease and not to 
population stratification. In the selection of cases a strict phenotypic definition is 
important to ensure a homogeneous population. To improve statistical power the 
selection of cases can be restricted to include those who are likely to have a high 
genetic load, e.g. extreme phenotypes or early onset of disease. Controls can be 
randomly selected from the general population with unknown disease status or 
selected on the criteria to be healthy from the disease under study. The use of 
healthy controls in association studies of common diseases is preferable due to 
the loss of power using randomly selected individuals from the general 
population [24,25]. The completion of the International HapMap project 
encouraged the development of SNP-based GWAS. GWAS interrogates the 
whole genome at once using tSNPs and selected non-synonymous SNPs and 
have become a popular method for the investigation of common variants. 
Illumina (http://www.illumina.com/) provides genotyping arrays containing up 
to 5 million genetic markers that can be simultaneously analyzed. Since all of 
these genetic markers are all investigated for associations using different 
statistical methods, a large number of associations are expected purely by chance 
using the conventional threshold for significance at P < 0.05. Thus, multiple 
testing is one of the major issues with GWAS and stringent levels for 
significance have therefore been adopted [26]. In contrast to GWAS, candidate 
gene studies are hypothesis driven and the selection of genes for study can be 
made using several different strategies, e.g. genes selected from relevant 
biochemical pathways or genes implicated in previous studies. Even though 
GWAS have become very popular since their introduction, candidate gene 
studies are frequently reported in the literature. The strategy to investigate a 
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small number of candidate genes has some benefits compared to GWAS that 
might explain the frequent use of this approach. For example, the issue with 
multiple testing is less pronounced since the numbers of SNPs are much smaller 
compared to in GWAS. The SNPs analyzed in candidate gene studies are also to 
a larger extent more dependent through LD compared to in GWAS, and the 
correction for multiple tests can thus be less strict. It is also possible to choose a 
more complete set of functionally relevant SNPs. This makes the association 
results easier to interpret compared with SNPs located in intergenic regions far 
from known genes, which is often the case in GWAS. Lastly, the lower cost for 
genotyping a much smaller total number of SNPs is of course also a major factor 
speaking in favor of candidate gene studies.  
1.5.3 Hardy-Weinberg equilibrium 
The rediscovery of Mendel’s laws in 1900 raised the question of their relevance 
for the genetics of populations. This lead to the development of modern 
population genetics. One of the first important results within this discipline 
appeared in 1908, when the English mathematician G. H. Hardy and the German 
physician W. Weinberg concluded that the expected genotypes of a random 
mating population can be calculated using allele frequencies of that specific 
population [27]. The allele frequencies of alleles A and a is p and 1-p = q, 
respectively. Thus, p+q = 1 and the frequencies of the genotypes AA, Aa and aa 
under Hardy-Weinberg equilibrium (HWE) are expected to be p2, 2pq and q2, 
respectively. A test for HWE using a chi-square test or Fishers exact test is 
primarily made as a quality control of the genotype data in association studies. 
Departures from HWE can be due to genotyping problems where genotypes are 
being miss-interpreted. Also the existence of sub-population structures or actual 
association signals can lead to departures from HWE, even though the test have 
limited power to detect these circumstances [24,28].  
1.5.4 Association analysis 
The allele and genotype counts of both cases and controls can be tabulated in 
contingency tables and standard statistical tests can be used to test the null 
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hypothesis of no association. The chi-squared 2-degree of freedom test is often 
used when investigating the distribution of genotypes among cases and controls. 
The test compares the observed distribution of genotypes among cases and 
controls with the expected distribution. The test has a reasonably high power to 
detect associations regardless of the underlying risks. If the underlying genotype 
risks are additive, a chi-squared 1-degree of freedom test to consider the 
distribution of alleles among cases and controls is more powerful. However, 
using this approach requires an assumption of HWE in the combined samples of 
cases and controls. An alternative test to the chi-squared 1-degree of freedom test 
that do not rely on the assumptions of HWE is the Cochran-Armitage test [28]. 
1.5.5 Multiple testing 
In association studies that involve a large number of SNPs, false positive results 
are expected. Given the conventional significance threshold of 0.05, one test out 
of 20 is expected to be significantly associated by chance only, i.e. false positive 
associations are a common phenomenon when many tests are performed. 
Therefore the significance level of the individual tests, which is the probability 
for making a type-I error, has to be adjusted. In GWAS where the number of 
tests can be in the order of millions, a threshold for significance has been widely 
adopted at 5x10-8 to reduce the number of false positive associations. One way to 
lower the significant threshold is by applying a Bonferroni correction, in which 
the conventional significance level of 0.05 is divided by the number of tests. 
Since SNPs can be correlated through LD, the corresponding tests for 
associations will not be independent. Consequently, the Bonferroni correction is 
very conservative and the significance threshold will be overcorrected [26]. 
Instead of lowering the significance threshold, an alternative approach is to 
estimate the false-discovery rate (FDR), which is the proportion of false positive 
results among all tests identified as significant. The q-value is an extension of the 
FDR and is similar to the P-value. Each test is associated with a q-value that 
measure the proportion of false positives when considering all P-values equal to 
or more extreme than the associated P-value for the test under consideration 
[29]. 
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1.5.6 Odds ratio 
The P-value of an association test between marker and phenotype gives 
information of the statistical evidence of the association. This is only one aspect 
of the data. An equally important aspect is the risk for disease given the effect of 
specific SNP alleles or genotypes, if a SNP is considered to be associated with 
the disease. This can be calculated through odds ratios (ORs). ORs are calculated 
as the odds for cases having a specific allele over the odds for controls having 
the same allele. It is common practice to calculate accompanying 95% 
confidence intervals for ORs that describes the probability of the estimates [25].   
1.6 ALLERGIC AIRWAY INFLAMMATION 
1.6.1 Allergic rhinitis 
Allergic rhinitis (AR) is a global health problem that causes major disability 
worldwide. It is due to an allergen induced IgE-mediated inflammation of the 
membranes lining the upper airways. Nasal obstruction, secretion and itching are 
characterizing features of the disease, which is often associated with eye 
symptoms, fatigue and asthma. The impact of AR on health-related quality of 
life, work and school performance are well recognized [30]. The widely debated 
hygiene hypothesis as origin for the development of allergy is based on the 
observation that early childhood exposure to parasitic infections and other 
microorganisms has been reduced due to better standard of living. Such 
infections encourage a normal development of the immune responses. As the 
exposure to such infections has been reduced in the modern society, there is a 
tendency for certain individuals to develop immune responses against harmless 
environmental allergens [31]. The development and severity of AR are 
determined by a complex interaction between both environmental and genetic 
factors and are not fully understood.  
1.6.2 Asthma 
Asthma is a common chronic inflammatory disease of the airways characterized 
by variable and recurring symptoms, reversible airflow obstruction and 
bronchospasm. Symptoms include wheezing, coughing, chest tightness, and 
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shortness of breath. It includes hyper reactivity to a variety of stimuli and 
remodeling of the airways [32,33]. The development of asthma is due to a 
complex interaction between both genetic and environmental factors and the 
heritability of asthma has been estimated to 0.5-0.6 in twin and family studies 
[34].  
1.6.3 Genetics of allergic rhinitis and asthma 
Although AR does not demonstrate Mendelian inheritance, the heritability for 
AR is relatively high and has been estimated to 0.66-0.78 [35,36]. Although 
more than 100 SNPs have been associated with the disease, the genetic basis for 
AR is poorly understood. Genetic findings in AR has primarily been identified 
through candidate gene studies, but the associations have been difficult to 
replicate in later studies [37,38]. To date, four GWAS have been published 
investigating AR and allergic sensitization, i.e. the presence of allergen-specific 
IgE. In a GWAS of a Singapore Chinese population, analysis of 456 AR cases 
and 486 controls identified no genome-wide significant SNPs for AR. However, 
after replication of 77 SNPs in a replication cohort of 676 AR cases and 511 
controls suggestive associations were identified for two SNPs in the BCAP and 
MRPL4 genes [39]. A meta-study of GWAS (mGWAS) investigating self-
reported AR and grass sensitization in 6248 cases and 18 997 controls identified 
three loci (HLA-DRB4, C11ORF39 and TMEM232) at a genome-wide 
significance level (P < 5x10-8) and an additional 12 loci with suggestive 
associations (5x10-8 < P < 5x10-6). Using the data set in a candidate gene 
approach, identified an additional three genes as associated with the investigate 
phenotypes (TSLP, TLR6 and NOD1) [40]. A second mGWAS investigated 
allergic sensitization in 11 903 cases and 19 976 controls of European ancestry. 
The study identified a total of 10 loci at a genome-wide significance level (P < 
5x10-8), including TLR6, C11orf30, STAT6, SLC25A46, HLA-DQB1, IL1RL1, 
LPP, MYC, IL2 and HLA-B [41]. A third mGWAS investigated self-reported cat, 
dust-mite and pollen allergies in 27 551 cases and 26 311 controls. A total of 16 
genome-wide significant loci (P < 5x10−8) and an additional 6 loci with 
suggestive evidence of association (5x10−8 < P < 1x10−6) were identified in the 
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study. The detected associations were located in the regions of TLR1-TLR6, 
WDR36-CAMK4, C11orf30-LRRC32, IL1RL2-IL1RL1, HLA-DQA1-HLA-
DQB1, HLA-C-MICA,  PTGER4, PLCL1, LPP, RANBP6-IL33, NFATC2, 
GSDMB, SMAD3, GATA3, ADAD1, FOXA1-TTC6, TPD52-ZBTB10, ID2, 
CLEC16A, IL4R-IL21R, PEX14 and ETS1. Several of these loci have previously 
been associated with other immunity-related phenotypes including asthma [42]. 
Allergic disease like AR and atopic asthma have an overlapping etiology in for 
example increased levels of IgE which may indicate a common genetic 
background (at least in part) for these diseases. In addition, patients with AR 
have a 5-6 fold increased risk of developing asthma [43-45]. In asthma, the 
genetic background has been more extensively studied compared to the genetics 
of AR. GWAS investigating asthma phenotypes have identified more than 18 
susceptibility loci for the disease and the ORMDL3/GSDML, HLA-DR/DQ, IL33 
and IL18R1/IL1RL1 loci have been consistently identified in multiple asthma 
GWAS [34]. A large number of asthma-associated genes from different types of 
studies have been positively associated multiple times. The ARDB2 gene have 
for example been identified more than 40 times, and IL13, HLA-DRB1 and IL4R 
have been associated with asthma phenotypes more than 25 times [46].   
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2 AIMS 
The overall aim of this thesis has been to identify genetic variants associated 
with allergic rhinitis (AR).  
When I started my PhD studies in 2009, genetic association studies in AR were 
mostly carried out as candidate gene studies based on relatively small sample 
sizes and few of the identified associations had been replicated. Accordingly, 
paper I of this thesis aimed to investigate the reproducibility of such previously 
reported candidate gene associations in AR. 
The genetic background for asthma has been far more investigated compared to 
the genetics of AR and many asthma-associated genes have been successfully 
replicated. It is also well known that asthma is closely related to AR. Thus, 
paper II aimed to examine genetic variation in highly replicated asthma-
associated genes for associations also in AR. 
Three mGWAS investigating AR were published in 2011-2014. These studies 
made important contributions to the field of AR genetics since all used large 
numbers of cases and controls and identified highly significant loci that were 
also detected in several of the studies. Therefore, paper III aimed to investigate 
the reproducibility of these associations. In addition, the study also investigated 
these associations for age at onset effects.   
The Toll-like receptors (TLRs) have been extensively studied in various allergic 
diseases including AR and a number of studies have identified associations with 
variants in the TLR genes. Paper IV aimed to search for common genetic 
variants associated with AR in the TLR genes. 
Common variants are not able to explain the phenotypic variability of complex 
disease more than to a minor degree. This missing heritability is often argued to 
be due to the presence of detrimental rare variants present in addition to the 
common factors. Paper V aimed to characterize rare genetic variants in the TLR 
genes and to investigate the possibility for an accumulation of rare and 
detrimental variants in AR patients. 
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3 MATERIALS AND METHODS 
3.1 SUBJECTS 
Three different study populations have been investigated in the present work, 
two Swedish populations and one Singapore Chinese population. 
3.1.1 Swedish Malmö population  
The first population is a Swedish study population from southern Sweden. It was 
recruited at Malmö University hospital in 2003-2009 and consists of unrelated 
subjects from the general population. Both patients and controls were of 
Caucasian origin, with both parents born in Sweden. The diagnosis of birch 
and/or grass pollen induced AR was based on a positive history of intermittent 
AR for at least 2 years and a positive skin prick test (SPT; mixture of 11 
common airborne allergens, ALK-Abelló, Hørsholm, Denmark SPT) or 
Phadiatop test (mixture with 8 different inhalant allergens, Pharmacia Upjohn, 
Uppsala, Sweden) to birch and/or grass. SPT were performed on the volar side of 
the forearm with saline buffer as negative and histamine chloride (10 mg/ml) as 
positive controls. A wheal reaction diameter of ≥3 mm was considered a positive 
SPT response. SPT was only performed if the AR cases had not taken any anti-
allergic drugs for at least 3 days prior to the test. All patients were classified as 
having severe symptoms (itchy nose and eyes, sneezing, nasal secretion and 
nasal blockage) during pollen season and they had all been treated with 
antihistamines and nasal steroids during pollen seasons previous years. Controls 
had no history of AR or any other atopic disease and had a negative SPT or 
Phadiatop test. Data for a total of 1061 individuals were included in the analysis. 
The study was approved by the Ethics Committee of the Medical Faculty, Lund 
University, and written informed consent was obtained from all subjects.  
3.1.2 Swedish BAMSE population 
The second Swedish population was derived from the Stockholm area as part of 
the BAMSE study [47,48]. The BAMSE study is an unselected population-based 
birth cohort and consists of 4089 children recruited between February 1994 and 
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November 1996. All participants were living in the northern and central parts of 
Stockholm, Sweden, and were of mixed social economic status and from urban, 
suburban and inner city areas. Each participant and parents and/or legal 
guardians were given questionnaires concerning allergies, social economic 
status, housing and birth place of the parents. Follow-up studies were made at 1, 
2, 4, 8, 12 and 16 years of age. Allergy data were obtained at 4, 8 and 16 years of 
age. Sera were screened with Phadiatop and fx5 (mixture with 5 different food 
allergens, Pharmacia Diagnostics AB) at each evaluation. Sera with 
immunoglobulin E-value for Phadiatop and/or fx5 ≥ 0.35 kUA/l were then further 
analyzed for reactivity to the single allergens. Data from the 8 and 16 year 
evaluations for a total of 2153 children were included in the analysis. The 
BAMSE study was approved by the Ethics Committee at Karolinska Institutet, 
Stockholm, Sweden, and written informed consent was obtained from parents 
and/or legal guardians. 
3.1.3 Singapore Chinese population 
The third population was collected in Singapore using multiple recruitment-
drives and consists of unrelated Chinese individuals. All AR cases exhibited 
symptomatic house dust mite induced AR whereas the participating controls had 
no atopy and allergic symptomology. Diagnostic procedure included personal 
interview of medical history using a standardized questionnaire and SPT 
performed using standard panels of common allergens such as 
Dermatophagoides pteronyssinus and Blomia tropicalis. Data for a total of 2221 
individuals were included in the analysis. This study was approved by the 
Institutional Review Board (IRB, Reference - NUS07-023) of National 
University of Singapore and is also in compliance with the Helsinki declaration. 
All DNA samples were collected following standard protocols of informed 
consent. 
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3.2 DNA EXTRACTION 
DNA was extracted from blood or buccal cells. DNA concentrations were 
determined by fluorometry using PicoGreen (Molecular Probes, Eugene, OR, 
USA) or by Nanodrop (Thermo Fisher Scientific Inc, Wilmington, DE, USA). 
3.3 GENOTYPING 
Determination of small and medium numbers of SNP genotypes were either 
performed using a TaqMan-based strategy or a Sequenom MassARRAY 
MALDI-TOF strategy. Dual-labelled TaqMan-assays were carried out at 
Kristianstad University according to the manufacturer’s protocol using either 
ABI PRISM 7900HT (Applied Biosystems, Foster City, CA, USA) or CFX384 
(Bio-Rad, Hercules, CA, USA) genotyping systems. The Sequenom 
MassARRAY MALDI-TOF system (Sequenom Inc, San Diego, CA, USA) 
analyzed allele-specific primer extension products using mass spectrometry. 
Assay design was made using the MassARRAY Assay Design ver. 2.0 software 
and primers were obtained from Metabion GmbH (Martinsried, Germany). 
Sequenom genotyping was made at the Mutation Analysis Facility at Karolinska 
Institutet. Determination of large numbers of genotypes, i.e. whole genome 
genotyping was performed using the Illumina HumanHap 550 k BeadChip 
version 3 (Illumina, San Diego, CA, USA) at the Genome Institute of Singapore. 
3.4 SANGER SEQUENCING 
Primers were designed using Primer-BLAST (http://www.ncbi.nlm.nih.gov/ 
tools/primer-blast/) and purchased from DNA Technology A/S (Risskov, 
Denmark). Big Dye Terminator Sanger sequencing was performed in both 
directions using a 3130XL Genetic Analyzer (Applied Biosystems). Primary 
PCR was performed using KAPA Taq Extra HS PCR Kit (KAPA Biosystems, 
Cape Town, South Africa) and primary PCR products were treated with 
ExoSAP-IT® (Applied Biosystems) according to the manufacturer’s 
instructions. DNA sequencing was subsequently performed in a total volume of 
5 µl containing 0.5X Big Dye sequencing ready reaction premix (Big Dye 
Terminator v 2.0, Applied Biosystems), 0.5X Big Dye Sequencing buffer and 
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3.2 pmol of the sequencing primer. The sequencing reactions were purified using 
Xterminator (Applied Biosystems) according to the manufacturer’s instructions. 
Sequences were interpreted and all polymorphisms were identified using 
SeqScape ver. 2.5 and confirmed by manual inspection. 
3.5 ION TORRENT SEQUENCING 
The primers were designed using Ion AmpliSeq Designer, pipeline version 2.0.3 
(http://www.ampliseq.com). Template DNA was pooled such that each pool 
contained equimolar amounts of DNA from 12 individuals. Initial amplification 
of the targeted regions was performed using the Ion AmpliSeq™ Library Kit 2.0 
(Life Technologies, Carlsbad, CA, USA) in 10 µl PCR reactions using 20 ng of 
template DNA. Adapters were subsequently ligated to each pool of amplicons 
and clean-up and size selection was performed using Agencourt Ampure XP 
beads (Beckman Coulter, Indianapolis, IN, USA). DNA concentration and 
fragment size distribution of each library were determined by capillary 
electrophoresis on a Fragment Analyzer (Advanced Analytical Technologies Inc, 
Ames, IA, USA). The libraries were then diluted and emulsion PCR performed 
using a OneTouch 2 machine (Life Technologies) with the Ion PGM Template 
OT2 200 kit (Life Technologies). Templated spheres were recovered using Ion 
PGM Enrichment Beads (Life Technologies). The samples were centrifuged and 
the resuspended pellets were mixed with sequencing primer from Ion PGM 
Sequencing 200 kit v2 (Life Technologies). The sequencing primer was annealed 
by incubation followed by the addition of sequencing polymerase. The samples 
were loaded onto an Ion PGM 314 chip v2 (Life Technologies) and sequencing 
performed on an Ion Torrent PGM (Life Technologies) using the default flow 
order. The sequences were aligned against the human reference sequence (build 
GRCh37) using Torrent Suite 3.6 (Life Technologies) and primer sequences 
were trimmed off. Variant calling was performed using parameters tuned for 
high sensitivity. Annotation of the detected SNPs was made using SeattleSeq 
Annotation 137 (http://snp.gs.washington.edu/SeattleSeqAnnotation137/). 
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3.6 STATISTICAL ANALYSIS 
Statistical analyses were made using R statistical software [49,50] and PLINK 
v1.07 [51]. Genotype frequencies were calculated and tested for Hardy-
Weinberg equilibrium in both cases and controls. Allele and genotype 
frequencies were then investigated for association with AR using χ2-
homogeneity tests. Odds ratios (ORs) and 95% confidence intervals were 
estimated by using the most common allele as the referent and are reported for 
each minor allele. Associations between SPT response and genotype were 
analyzed using Kruskal-Wallis rank sum test. False discovery rate was quantified 
using the q-value introduced by Storey [52] and calculated using the R package 
qvalue v.1.32 [53]. Power calculations were made using simulations for the 
association tests of allele effects. For each SNP a data set was simulated with the 
actual numbers of cases and controls, using the published ORs and the allele 
frequencies observed in our populations. A total of 10 000 runs were made in 
each case. For these, a full data set was simulated and the 2-value was 
calculated. The number of times the test quantity exceeded the critical value 
(0.05 and 0.001) was subsequently scored. Age at onset effects were investigated 
using a likelihood ratio test investigating the heterogeneity of age classes when 
AR cases were stratified into those with early onset ( 8 years of age) and those 
with late onset (> 8 years of age). The potential impact of asthma was evaluated 
by partitioning the difference in allele frequencies observed between cases and 
controls into three different components. The first component (C1) being the 
difference in risk allele frequency between cases and controls in the absence of 
asthma, i.e. the difference that we aim to investigate. The second component 
(C2) represents the direct confounding due to the combined effect of an excess 
of asthmatics among cases and the difference in allele frequencies between cases 
with or without asthma. The third component (C3) is due to the interaction 
between allergy and asthma on their effect on the risk allele frequency.  
3.7 BIOINFORMATICS 
tSNPs were selected using HapMap (http://www.HapMap.org) CEU data and the 
tagger function implemented in Haploview v.4.2 [54] and missense and 
  31 
nonsense variants were extracted from dbSNP 
(http://www.ncbi.nlm.nih.gov/SNP/). Polymorphisms were extracted from 
dbSNP and 1000Genomes (http://www.1000genomes.org/) databases. The 
variants were obtained from the Integrated Variant Set of the 1000Genomes 
Project (http://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20110521/) release 
April 2012. Variants were extracted for 1092 individuals using tabix [55]. Using 
VCFtools [56] this data set was then subdivided into four separate populations; 
individuals of European (EUR; 379 individuals), African (AFR; 246), Asian 
(ASN; 286) and South American origin (AMR; 181). Missense mutations 
identified in the study population and in the 1000Genomes population were 
investigated using SIFT [57] and PolyPhen-2 [58]. 
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4 RESULTS 
4.1 PAPER I 
More than 100 SNPs have been associated with AR, predominantly through 
candidate gene studies. However, few of these associations have been replicated. 
Replication of previous associations is considered to be an important step in 
validating associations and an association is not to be considered reliable until it 
has been properly replicated.      
Paper I presents an investigation of the general reproducibility of associations 
between AR and previously identified candidate SNPs. A total of 49 SNP 
markers were genotyped in one Swedish and one Chinese population. The 
Swedish study population consisted of 352 AR patients and 709 healthy control 
individuals, and the Chinese population of 948 AR patients and 580 control 
individuals.  
According to the published ORs most of the previously identified candidate 
SNPs showed high power to detect significant AR associations in both 
populations of the present study. However, the overall result of the association 
study in paper I indicated that very few of the investigated SNPs were 
associated with AR. In the Swedish population, only 2 SNPs showed P-values 
below 0.05 and in the Chinese population there were 4. A FDR test was used to 
investigate the validity of the predictions. All of the indicated P-values gave rise 
to high false-discovery rates except 1 SNP in the Swedish population. Two other 
approaches were used in an attempt to identify additional potential associations. 
Correlation coefficients of ORs between the present and the original studies were 
calculated and the number of concordant and discordant SNPs in the direction of 
the ORs (>1 or <1) was also calculated. These approaches failed to detect 
convincing association signals for the investigated SNPs.    
Paper I summarizes previously reported AR associations and also emphasizes 
the difficulties in replicating associations and the need for large and well-
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characterized case and control materials to be able to successfully identify and 
replicate candidate SNPs in AR. 
4.2 PAPER II 
It is well known that asthma is closely related to AR. Compared to the genetics 
of AR the genetic background for asthma has been thoroughly investigated, and 
many asthma-associated genes have been successfully replicated. Thus, using 
genes that have been replicated multiple times in asthma as candidate genes for 
AR could be a successful approach to detect AR-associated genes given the co-
occurrence and partly shared etiology of the two diseases.  
Paper II uses the data presented for asthma in a study by Ober and Hoffjan [59] 
to search for AR associations. They reported 25 genes positively associated with 
asthma/atopy in six or more independent studies. Twenty-one of these genes 
were analyzed for association with AR in paper II using a total of 192 tSNPs 
covering these genes. Sequenom genotyping was made in a Swedish population 
consisting of 246 AR patients and 431 controls. Additionally, genotypes of 429 
tSNPs from the same genes were extracted from a Singapore Chinese GWAS 
cohort consisting of 456 AR cases and 486 controls. 
The overall association results corresponded well to the expectations in the 
absence of an effect for most markers. However, in the Chinese population the 
number of significant P-values exceeded the expectations. The strongest 
association signals were found for SNPs in CTLA4 and NPSR1. In each of these 
genes, more than one SNP showed P-values <0.05 with corresponding false-
discovery rates <0.05. In the NPSR1 gene some P-values were lower than the 
Bonferroni correction level. This result indicates that NPSR1 could be a genetic 
link between AR and asthma. In the Swedish population, weaker indications 
were found for IL13 and GSTP1 with respect to sensitization to birch pollen.  
The use of asthma genes as candidate genes for AR associations was an 
alternative way to identify genes involved in the development of AR. The fact 
that a few potential associations were found indicates that this was a successful 
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strategy. Yet, the number of detected associations is low and the difficulties of 
finding associations largely remain. 
4.3 PAPER III 
Three large mGWAS have been reported in different European and North 
American study populations. Together these studies defined a set of 47 SNPs 
associated with allergic sensitization and self-reported AR.  
In paper III, the well-characterized BAMSE cohort was used to investigate the 
reproducibility of the SNP associations detected in the three mGWAS. The 
replication was made using the same phenotype definitions as in the original 
studies. In addition, a more strict AR definition was used.  
An absolute majority of the observed risk alleles and the allele frequency 
differences between cases and controls were concordant with the results of the 
original studies and thus supports the previously reported associations. Two out 
of the four loci that were identified in all three original studies were also 
identified in the present study. The TLR1-TLR6 locus was identified by 3 index-
SNPs and the HLA-DQA1-HLA-DQB1 locus by 2 SNPs. In addition, the TSLP-
SLC25A46 locus that was identified in two of the original studies was identified 
also in the present study by 2 SNPs. These more frequently identified loci are 
strong candidates for harboring genetic variation truly associated with allergic 
disease. The tests for AR association using a more strict AR definition clearly 
identified the TLR1-TLR6 locus. Thus, this more clinically relevant definition did 
also detect this highly replicated locus. Two additional loci, SSTR1-MIPOL1 and 
TSLP-SLC25A46, were identified as being involved in the early onset of AR. 
4.4 PAPER IV 
The TLRs are important in activating immune responses upon recognition of 
different pathogens. Since they are central in regulating the immune response, 
the TLRs have been investigated for their involvement in different allergic 
diseases.  
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In paper IV a total of 73 SNPs covering 9 of the 10 TLR genes were genotyped 
in 182 AR patients and 378 control individuals in a first screen for association 
with AR. The association analysis revealed 1 significantly associated SNP in 
each of the TLR1, TLR6 and TLR7 genes, and TLR8 showed 3 SNPs with P-
values below 0.05. Based on the results from the association analysis, an 
additional 24 SNPs in the TLR7-TLR8 gene region were analyzed in one 
Swedish population with 352 patients and 709 controls and one Singapore 
Chinese population with 948 cases and 580 controls.  
Subsequent analysis of the 24 SNPs from the TLR7-TLR8 gene region identified 
7 and 5 significant SNPs in the Swedish and Chinese populations, respectively. 
The corresponding risk-associated haplotypes were significant after Bonferroni 
correction and were the most common haplotypes in both populations. The 
associations were primarily detected in females in the Swedish population, 
whereas it was seen in males in the Chinese population. Further independent 
support for the involvement of this region in AR was obtained from quantitative 
analysis of SPT data generated in both populations. 
4.5 PAPER V 
In paper V the putative promoter regions and coding sequences of the TLR 
genes (TLR1-TLR10) were searched for rare and common polymorphisms. The 
primary aims of the study were to search for an accumulation of rare variants in 
patients relative to controls and to identify AR associated-candidate mutations. 
Sequencing of 288 AR patients detected a total of 156 SNPs of which 37 where 
located in the promoter regions. In the coding sequence, 69 were missense 
mutations of which 30% were classified as damaging using both SIFT and 
Polyphen-2 predictions, 3 were nonsense mutations and 47 were synonymous 
polymorphisms. The distribution of variants among the TLR genes was highly 
uneven. TLR10, TLR1 and TLR6 that reside in the same chromosomal locus 
showed a high level of variation, whereas TLR7 and TLR8 which are located in a 
narrow region on the X-chromosome showed a low level of variation. 
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The number of rare variants (MAF ≤1%), AR-specific variants and damaging 
nonsense and missense variants in the investigated 288 AR patients were 
compared to the numbers obtained for 379 EUR individuals of the 
1000Genomes project (EUR). The overall results indicated no accumulation of 
rare variants in the AR population. Neither was there any overrepresentation of 
mutations classified as damaging by SIFT or PolyPhen-2 in the coding 
sequences. The only exception was the promoter region of TLR10 where a group 
of 6 variants were unique to the AR population. This result was supported using 
a simulation test (P=0.00009). Another potential exception was a nonsense 
mutation, S324* in TLR1, estimated to 5 copies in the AR population but none in 
the EUR population, which is a clear overrepresentation. These results in 
combination with the results of paper IV clearly indicate the major importance 
of the TLR10-TLR1-TLR6 locus for the development of AR.  
  37 
5 DISCUSSION 
A number of different strategies have been used in this thesis to identify genetic 
variation associated with AR. The first study examined the reproducibility of 
previously reported associations identified in small candidate gene studies. There 
were two main reasons for choosing this strategy. The first reason was to 
characterize the populations with respect to HWE and their ability to detect 
previous associations given different effect sizes. Another important reason for 
performing this study was the lack of published general replication attempts in 
AR. The strategy itself was of limited success since the reproducibility turned 
out to be very low. There are a number of reasons for this, but the major factors 
are probably that many of the early genetic studies in AR had small population 
sizes with heterogeneous phenotype definitions, resulting in false positive 
associations. There may of course be a number of true associations among the 
investigated SNPs, but their effect sizes are in that case very small resulting in a 
lack of statistical power for the association analysis in paper I. This illustrates the 
phenomenon that many early investigations in an area often are of limited value 
when it comes to the actual results, they have served merely as a test of 
methodology and concept. 
The second study investigated tSNPs from highly replicated candidate genes of a 
related disease. The genetic background in asthma is more thoroughly 
investigated than in AR and since asthma and AR have in part a shared etiology, 
the strategy to investigate these genes also for AR is not controversial. However, 
the genetic backgrounds for asthma and AR do not appear to overlap to any 
considerable degree, since only a few of the investigated genes were identified as 
candidate genes also for AR. Other studies have shown that some genes and loci 
are associated with both diseases, e.g. IL33 and HLA-DQ [38,42]. This indicates 
that these two diseases are related and share a common but limited genetic 
background. 
The third strategy was analogous to the first strategy, but instead of investigating 
risk SNPs identified in small candidate gene studies, this study investigated the 
reproducibility of risk SNPs from well-powered GWAS. The replication attempt 
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was made in a study population with limited statistical power, but with an 
extensive phenotypic characterization. This was advantageous since this made it 
possible to investigate these associations using exactly the same phenotype 
definitions that were used in the original studies. This approach was clearly the 
most successful so far, since the majority of the observed risk alleles and the 
allele frequency differences between cases and controls were concordant with 
the results of the original studies and 2 out of 4 loci that were identified in all 
three original studies were also identified in the replication study. This highlights 
the robustness of associations detected in well-powered studies. Since the two 
loci (HLA-DQA1-HLA-DQB1 and TLR1-TLR6) detected in all three original 
studies were detected also in the replication study this indicates the importance 
and central role of these loci in the development of AR.  
Another strategy used in this thesis was to investigate genes likely to be involved 
in the development of AR on the basis of their known biochemical and 
physiological functions. The fourth study investigated common variants in the 
TLR genes and resulted in a positive association of the TLR7-TLR8 locus in two 
different populations. In addition, weaker associations for the TLR1-TLR6 locus 
were also observed in the Swedish Malmö population. Since these two loci have 
been indicated in a number of previous studies in AR [60,61,40-42], these loci 
are highly likely to be involved in the development of AR. Given this result the 
TLR1-TLR10 genes were further investigated for rare variants. The fifth study 
identified an accumulation of rare variants in AR patients for the previously 
indicated locus TLR10-TLR1-TLR6 despite the fact that a limited number of AR 
patients were investigated. An obvious extension to this study would be to re-
sequence the entire TLR10-TLR1-TLR6 locus in additional AR patients and 
controls from the same population to search for additional accumulation of rare 
variants in AR patients. In light of the missing heritability encountered in many 
complex diseases the strategy to investigate patients for rare variants has become 
a popular avenue following the introduction of next-generation sequencing [10]. 
An interesting aspect of association studies is the almost philosophical question 
of when an association is to be considered a true association. One can of course 
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not be certain until repeated functional biochemical studies of a specific variant 
has been thoroughly examined, the actual mechanism has been explained and the 
effect measured. But when is it appropriate to take this step forward? Is it when 
the P-value of an association reaches a specific threshold or the association have 
been replicated in additional populations a specified number of times? In my 
opinion, the likelihood for an association to be true increases for every time an 
association has been replicated showing the same risk allele. If both common 
and rare variants of both SNPs and CNVs can be shown to be disease-associated, 
the likelihood increases even more. Based on the data analyzed in this thesis, the 
highly indicated locus TLR10-TLR1-TLR6 qualifies for this criterion, since it has 
been implicated in three large mGWAS [40-41] and in three different studies of 
this thesis investigating both common and rare variation. 
There is a general problem with the interpretation of replications in light of 
publication bias. We can tabulate the number of times a given association has 
been reported as successfully replicated in the literature. We do not know, 
however, how many times this particular replication has been attempted, but 
been unsuccessful and therefore in many cases unreported. A replication is still a 
replication, but since the underlying statistics of exactly how many attempts that 
have been made is unknown to us it is difficult to judge the true value of this 
type of results. The value of a replication attempt is also quite different 
depending on how it is made. If a single association is being replicated this says 
something about that particular association, but not so much more. However, if 
all claims for associations to a specific disease are investigated in parallel this 
will generate other types of information in addition to the level of replication of 
the individual associations. Obviously, it will report also the negative results 
where claimed associations will not replicate, but in addition to this it can be 
evaluated if certain associations are replicated more often than others. Such 
highly replicated associations may indicate the existence of pathways or genes 
that are more often involved in the development of the disease, in contrast to 
those that are less often replicated that can be contributing to the disease in a 
small number of cases only. In my opinion this latter type of replication studies 
is therefore much more valuable than the former. 
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Also the quality of the phenotyping and the size of the study material are very 
important factors. The classification of the material into cases and controls can 
be made in a number of ways depending on the exact definitions of cases and 
controls. For example, cases with severe disease can be used together with so 
called “super-controls” that are classified as very healthy according to some 
logic. This may be a more efficient way to identify genes that are associated with 
the disease in question. The exact clinical definitions often also vary, at least 
slightly, between different studies and this may of course affect the results. The 
size of the study population is directly related to the power of the study so a 
larger size is of course better. But also in this case it is important to control a 
number of other factors. An eventual subpopulation structure may cloud the 
picture and it is important to control for it or even select a homogenous study 
material. Cases collected as patients coming to one or several clinics are a 
convenient source of cases, but raises questions of how to obtain well-matched 
controls and may lack precision in the phenotyping of the patients. Cohort 
studies of newborns like in the BAMSE study have a lot of different advantages 
as for example; definition of study material before appearance of disease, very 
good phenotyping with follow-up over time and possibility to control for many 
socio-economic and environmental factors through the evaluation of 
questionnaires. 
 Assuming now that the TLR10-TLR1-TLR6 locus is indeed involved in the 
development of AR, how can we proceed? A logical first step would be to 
characterize the genetic variation of this complete genomic region in a large 
enough number of patients. Since both common variants showing frequency 
differences between cases and controls and rare variants showing an 
accumulation in cases relative to controls are identified, it seems that an unbiased 
investigation for all types of common and rare variants in the whole locus is the 
way to go forward. Thus, covering the locus with overlapping long range PCR 
amplicons would allow a direct screen for deletions after analysis using agarose 
gel electrophoresis and in combination with a scaffold of TaqMan-based copy-
number assays and relative quantitative PCR analysis this strategy would detect 
a majority of large deletions and duplications of this region. Also smaller 
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deletions would be detected using this scheme. The long-range PCR products 
could also serve as substrate in the re-sequencing of the complete region using 
Ion Torrent sequencing. If this re-sequencing uses pooling of individuals this 
would allow screening for polymorphisms in a large number of individuals. It is 
difficult to know exactly how many individuals that it is necessary to screen to 
obtain a large enough number of candidate risk variants, but screening 1000 
patients is clearly possible and would make a first evaluation possible. 
Assuming that this locus indeed is harboring risk-associated variants at some 
frequency, this gene may serve as a beach-head directing further studies to genes 
and proteins directly interacting with the genes and gene products of this locus. 
Such a strategy would allow analysis for epistatic interactions that are possibly 
generated between these genes and gene products. There is a possibility that such 
interactions give rise to strong effects that will explain considerably more of the 
variation of the trait than what the single factors do. Another possible approach 
for further studies would be to re-sequence the exomes of as many patients as 
possible. This is a more unbiased approach since it do not rely on any selection 
of genes for study. But is also a more demanding approach in terms of the 
number of individuals that must be analyzed to obtain a large enough data set to 
allow identification of the disease-associated genes. However, re-sequencing of 
exomes, much like GWAS, is suitable for meta-analysis and one obvious way 
forward is that researchers in the field join forces, each re-sequencing as many 
exomes that there funding will allow and then this data could be merged to one 
large data set with sufficient power to identify the elusive disease-associated 
genes that we are so eager to identify. 
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6 CONCLUSIONS 
Since the development of AR depends on both environmental and genetic 
factors, the individual effect of a single polymorphism is expected to be small. 
Large and well-characterized populations are therefore crucial for the 
identification of robust associations. Conversely, smaller populations with less 
stringent phenotyping are less likely to identify true associations. This is 
illustrated in paper I where 49 previously AR-associated SNPs were tested in a 
replication study. The original studies were all based on relatively small 
populations and the definition of AR also differed between the studies. The 
overall result showed a low replication rate and that very few of the investigated 
SNPs were associated with AR in the two populations used in the replication 
attempt. The study also indicated that the odds-ratios were inflated in most of the 
original studies, and a low concordance of risk alleles between the studies was 
observed.        
Replication studies are very important for validating reported associations. The 
genetic background of asthma has been extensively studied and replicating 
previous associations have been far more successful compared to AR. AR and 
asthma are considered to be closely related and genes that have been replicated 
multiple times in asthma might also turn out to be candidate genes for AR. In 
paper II this strategy was evaluated by investigating 21 genes highly replicated 
in asthma. The NPSR1 and CTLA4 genes were identified as potential links 
between AR and asthma, with NPSR1 as the strongest candidate. However, the 
majority of the investigated genes showed no or a modest level of association. 
Since the strategy to use asthma genes as candidate genes for AR only had 
limited success, it is tempting to suggest that genetics in AR and asthma might 
not share a common etiology to the extent that was previously argued for.  
GWAS have been a successful approach to identify potential candidate genes in 
complex diseases. Even though the identified variants only explain a small 
portion of the disease, they provide leads to relevant genes and biochemical 
pathways involved in the disease mechanisms. Three meta-GWAS investigating 
AR phenotypes successfully identified a total of 47 index SNPs at a genome-
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wide or suggestive association level. In paper III, these SNPs were investigated 
in a replication study using the same SNPs and the same phenotype definitions 
as in the mGWAS. The results showed a much higher replication rate than what 
was observed in paper I, indicating more robust associations. Two out of four 
loci (TLR6-TLR1 and HLA-DQA1-HLA-DQB1) identified by all three original 
studies were also detected in the replication study using the same phenotype 
definitions and a more strictly defined AR phenotype. These two loci are likely 
to have a central role in the epidemiology of allergic disease. In addition, 
associations between genetic variation in the SSTR1-MIPOL1 and TSLP-
SLC25A46 loci and age at which the allergic symptoms started was also 
identified. Notably, this was the first report of age at onset effects in allergic 
rhinitis. 
The Toll-like receptors induce a prompt immune response upon pathogen 
recognition. Since they are central in regulating the immune response, the TLRs 
have been investigated for their involvement in different allergic diseases. In 
paper IV, common genetic variation in the TLR-genes was investigated for 
association with AR in two ethnically different populations. The TLR7-TLR8 
locus was identified as associated with AR in both populations in a sex-specific 
manner. However, different sexes were associated in the respective populations 
probably reflecting the loss of power when investigating X chromosomal SNPs 
in men. In addition, weak associations were also observed for TLR1 and TLR6. 
Since the TLR genes has been found to harbor genetic variants associated with 
AR in a number of different studies it is highly likely that these genes contribute 
to the development of AR. In the previous studies, focus has primarily been on 
common variation. In paper V the focus is shifted towards rare variation in both 
the coding sequence and the putative promotor regions. Comparisons of TLR 
sequence data from 288 AR patients with a European subset of the 
1000Genomes project showed limited signs of accumulation of rare variants in 
the AR population. Also, no signs of any excess of damaging missense 
mutations were observed. The promotor region of TLR10 was an exception from 
this general trend, where a total of six SNPs with MAF < 1% were detected in 
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the AR population. These SNPs were not present in the European subset or any 
of the other populations of the 1000Genomes project. Another potential 
exception was a nonsense mutation, S324* in TLR1, estimated to 5 copies in the 
AR population but none in the EUR populations, which is a clear 
overrepresentation. This indicates that both common and rare SNPs in the TLR 
genes contribute to AR. 
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